A method for the quantitative analysis of endothelin peptides in human umbilical vein endothelial cell (HUVEC) culture supernatants is reported. The analysis is isoform-specific and employs solid-phase extraction and subsequent HPLC fractionation followed by HPLC-ESIMS analysis. The peptide vasoactive-intestinal-contractor (VIC) was used as internal standard for the HPLC-ESIMS analysis. Linearity of calibration curves was from 50 fmol to 25 pmol. The limit of detection of the HPLC-ESIMS step using a buffer matrix was estimated at 50 fmol (S/N>> 3). The overall limit of detection for supernatants of HUVEC was 500 fmol/mL. In HUVEC culture supernatants only ions of endothelin-1 (ET1) were observed. Basal levels were determined to be 1.8 +/- 0.3 pmol/mL. Quantitative results obtained for ET1 were in agreement with those obtained by using a standard addition method and by an ELISA method.

Endothelins are powerful vasoconstrictor peptides that play numerous other roles. Endothelin-1 (ET1) is the principal isoform produced by the endothelium in the human cardiovascular system. Endothelin-3 (ET3) and its rPptor affinity have been demonstrated to support neuronal repair mechanisms throughout life. In multiple sclerosis (MS), the role of vasoactive peptides are not well defined. Here we focus on ET3, specifically the plasma levels between MS patients and healthy subjects. Furthermore, we evaluated the changes in ET1 and ET3 plasma levels during different disease phases, the correlation between ET3 and cerebral circulation time, and the relationship between ET1 and ET3. In MS patients, the ET3 plasma levels were altered in a time-dependent manner. These results could support a putative role of ET3 in neuroprotection and/or neuroimmune modulation over time.

Keywords: blood-brain barrier; cerebral circulation time; endothelin-3; multiple sclerosis (MS); neuroimmune modulation.

In addition to chemical composition, the site of deposition of inhaled particles is important for determining the potential health effects from an exposure. As a result, the International Organization for Standardization adopted a particle deposition sampling convention. This includes extrathoracic particle deposition sampling conventions for the anterior nasal passages (ET1) and the posterior nasal and oral passages (ET2). This study assessed how well a polyurethane foam insert placed in an Institute of Occupational Medicine (IOM) sampler can match an extrathoracic deposition sampling convention, while accounting for possible static buildup in the test particles. In this way, the study aimed to assess whether neutralized particles affected the performance of this sampler for estimating extrathoracic particle deposition. A total of three different particle sizes (4.9, 9.5, and 12.8 µm) were used. For each trial, one particle size was introduced into a low-speed wind tunnel with a wind speed set a 0.2 m/s (∼40 ft/min). This wind speed was chosen to closely match the conditions of most indoor working environments. Each particle size was tested twice either neutralized, using a high voltage neutralizer, or left in its normal (non neutralized) state as standard particles. IOM samplers were fitted with a polyurethane foam insert and placed on a rotating mannequin inside the wind tunnel. Foam sampling efficiencies were calculated for all trials to compare against the normalized ET1 sampling deposition convention. The foam sampling efficiencies matched well to the ET1 deposition convention for the larger particle sizes, but had a general trend of underestimating for all three particle sizes. The results of a Wilcoxon Rank Sum Test also showed that only at 4.9 µm was there a statistically significant difference (p-value = 0.03) between the foam sampling efficiency using the standard particles and the neutralized particles. This is interpreted to mean that static buildup may be occurring and neutralizing the particles that are 4.9 µm diameter in size did affect the performance of the foam sampler when estimating extrathoracic particle deposition.

One of the challenges to the dose assessment team in response to an inhalation incident in the workplace is to provide the occupational physicians, operational radiation protection personnel and line managers with early estimates of radionuclide intakes so that appropriate consequence management and mitigation can be done. For radionuclides such as Pu, where in vivo counting is not adequately sensitive, other techniques such as the measurement of removable radionuclide from the nasal airway passages can be used. At Los Alamos National Laboratory (LANL), nose swabs of the ET1 region have been used routinely as a first response to airborne Pu releases in the workplace, as well as for other radionuclides. This paper presents the results of analysing over 15 years of nose swab data, comparing these with dose assessments performed using the Bayesian methods developed at LANL. The results provide empirical support for using nose swab data for early dose assessments. For Pu, a rule of thumb is a dose factor of 0.8 mSv Bq(-1), assuming a linear relationship between nasal swab activity and committed effective dose equivalent. However, this value is specific to the methods and models used at LANL, and should not be applied directly without considering possible differences in measurement and calculation methods.

Dose calculations using the respiratory tract model presented in Publication 66 of the International Commission on Radiological Protection (ICRP) frequently predict that the basal cells of the anterior portion of the nose, the extrathoracic region ET1 of the model, are the most highly irradiated tissue of the body. The dose to the basal cells is averaged over a layer of tissue 10 microm thick located at a depth of 40 microm into the airway. Reported here are the results of a series of absorbed fraction calculations undertaken to compare with values tabulated in ICRP Publication 66. The Monte Carlo code MCNP4B and the geometric model of the ET1 region specified in Publication 66 were used in the calculations. Although some calculated differences are evident between the two sets of absorbed fractions, typically less than 20%, the calculations confirm that the electron absorbed fractions tabulated in Publication 66 are not responsible for the high estimates of the ET1 dose.

BACKGROUND

It is still unknown whether ischemia‑inducing training in patients with stable angina is superior to the training conducted below the ischemic threshold (IT) according to the current guidelines.

OBJECTIVE

The aim of the study was to assess the influence of warm‑up ischemia prior to training on the effects of training conducted either at or below the IT in patients with stable angina.

METHODS

Thirty male patients aged 56 ±8 years, after myocardial infarction, with stable angina and positive exercise test (ET1) were divided into 2 groups: group A included 18 patients with the warm‑up effect, group B - 12 patients without this effect. All patients followed an 8‑week interval training program (TP). The intensity of training was planned to reach the heart rate at the IT. Successive ETs were performed immediately after the TP (ET2), at day 3 (ET3), day 10 (ET4), and at 1 month (ET5).

RESULTS

After the TP, there was a statistically significant improvement in group A in all analyzed variables except maximum ST depression (max STD). Maximal workload increased by 28%, walking distance by 24%, duration by 20%, and time to 1‑mm STD by 28%. Max STD reduction amounted to 14% (P =0.13). The beneficial effect of training on exercise‑induced ischemia was maintained for up to 10 days (ET4) and on physical capacity for up to 1 month (ET5). In group B, the TP did not affect time to 1‑mm STD, but physical capacity improved significantly and was maintained for up to 1 month (ET5).

CONCLUSIONS

The warm‑up effect appears to be necessary to attenuate myocardial ischemia after training.

The purpose of this manuscript is to define the benefit of exercise test and peak inspiratory flow (PIF) measurement in adult patients with bronchial asthma. Seventy-seven patients--forty-seven from examined group (21 women, 26 men) and thirty patients from control group (8 women, 22 men) participated in this study. Exercise tests (ET) were performed in all subjects in the beginning of the study (ET1) then repeated two months later (ET2) only to the examined group. Patients exercised on a bicycle ergometer for 8-10 minutes to increase the hart rate to submaximal level. Spirometry were performed before and after the study and 5, 10, 15 and 20 minutes later. Symptoms of asthma after exercise and forced expiratory flow in one second (FEV1) decrease more then 15% of predicted value confirmed the diagnosis (positive test result). Thirty patients (74.4%) from examined group had positive results in ET1 and twelve (25.5%)--negative. Four patients (10%) were positive in ET2 and thirty-six (90%)--negative. deltaFEV1 decrease in ET2 was (-14.78%), in ET2 (-4.45%) p < 0.0001. There were twenty-nine (96.6%) negative results in control group, only one (3.4%) positive, p < 0.001. During the study no side effects were observed. The comparison of deltaPIF decrease in ET1 (-11.94%) and ET2 (-7.39%) shows significant difference p < 0.05. PIF decrease was not statistically different between control and study group. Results of the study suggest that exercise tests are safe and easy method of diagnosis and management of asthma. PIF measurement seems to be non-useful in diagnosis of bronchial asthma. It must be confirmed in further studies.

Plasma endothelin 1 (ET1) was determined by radioimmunoassay in 28 cases of acute attack of asthma (attack group), 23 subjects of non-symptomatic asthma (remission group) and 20 normal volunteers (control group). The results showed that the plasma ET1 in attack group (13.4 +/- 5.2 fmol/ml) was much higher than that in both remission group (8.4 +/- 3.9 fmol/ml, P < 0.01) and control group (6.6 +/- 2.6 fmol/ml, P < 0.01). However, there was no significant difference between remission group and control group. The plasma ET1 level revealed notably negative correlation to PaO2 and FEV1% (r = -0.8257, r = -0.8157, P < 0.01). The results suggested that ET1 probably involved in pathophysiologic process of acute attack of bronchial asthma.

To explore the pathophysiological roles of endothelin isopeptides and receptor subtypes in asthmatic responses, a guinea pig model for asthma was used to test the effects of antiendothelin (ET) serum and selective ET receptor antagonists for antigen-induced specific airway conductance changes as measured by whole-body plethysmography. In this model, all of the animals so far tested demonstrated both the immediate and late asthmatic responses. Although preimmune serum had no apparent effects, anti-ET antiserum suppressed the maximal reduction of specific airway conductance in both the immediate and late asthmatic responses, which suggested that ET(s) are involved in the pathophysiology of both the immediate and late asthmatic responses. The ETB selective antagonists, BQ788 and RES701-1, blocked the immediate asthmatic response but not the late asthmatic response, whereas the ETA antagonists, BQ123 and (Shionogi) 97-139, suppressed only the late asthmatic response without influencing the immediate asthmatic response. In vitro constrictive responses of isolated tracheas and bronchi to ET1 were inhibited mainly by BQ123 and BQ788, respectively, which suggested that distribution of ETA and ETB receptors for bronchoconstriction are topographically distinct along airways. Furthermore, thromboxane A2 and platelet activating factor (PAF) antagonists were effective in suppressing the late asthmatic response but not the immediate asthmatic response. Taken together, our present observations suggest that ET(s) influences pulmonary functions by constricting airway smooth muscle via ETB receptors during the immediate asthmatic response and by modulating pulmonary inflammation via ETA receptors during the late asthmatic response, respectively.

Endothelin-1 (ET-1) is an effective vasoconstrictor and has bronchoconstricting property. Recent findings in vivo and in vitro indicate the influence of ET-1 on bronchial smooth muscle tone. ET-1 concentration was detected in BAL-Fluid in patients with bronchial asthma. Previous studies indicated an increase in ET-1 serum concentrations in the course of exacerbation of asthma. The purpose of our study was to compare ET-1 concentrations in sera of asthmatics during the asymptomatic period and after metacholine provocation. The study was performed in a group of 16 patients with mild bronchial asthma and in 11 healthy subjects. ET-1 concentrations in sera were evaluated by Elisa method (kit R&D USA). Bronchial provocation with metacholine was performed in asthmatics using Bronchoscreen. The result was considered as positive with FEV1, decrease of at least 20%. Airway responsiveness to metacholine was expressed as PC20. The results were analyzed statistically by means of the Student's test. The baseline ET-1 levels in sera of healthy donors were lower then in asthmatics group (x1' = 4.72 +/- 1.01, x1 = 11.53 +/- 3.68 pg/ml, p < 0.001). We found a statistically significant increase of ET1-1 concentration in sera after inhalation of metacholine (x1 = 11.55 +/- 3.68; x2 = 24.08 +/- 4.09 pg/ml, p < 0.001). The results indicate that ET-1 may play a role in bronchospasm in asthmatics.

The extrathoracic airways and lymph nodes have not yet been represented explicitly in mathematical or stylized models of the human body utilized in the transport of photons internally between source and target organs. Currently, the ICRP assumes that the extrathoracic airways are reasonably approximated by using the thyroid or brain as the surrogate source and target region within the ICRP 66 respiratory tract model. In the present study, a new mathematical model was created to explicitly consider the extrathoracic airways, as well as other respiratory structures in the thorax of the adult. The model incorporates the MIRD model of the adult head and neck, and the ORNL model of the adult torso/legs. Additional defining equations are established for the external nose, nasal cavity, nasal sinuses (frontal, ethmoid, sphenoid, and maxillary sinuses), oral cavity, larynx, pharynx, trachea, and main bronchi. Use of the thyroid as a surrogate source for photon emissions in the ET1 and ET2 tissues is shown to provide either close or conservative values of specific absorbed fraction to target organs such as the lungs or breasts at energies exceeding 50-100 keV. At lower energies, surrogate-region values of SAF underestimate dose to target organs in ways highly dependent upon the source/target configuration. The use of the brain as a surrogate source for ET1 and ET2 tissues irradiating the thyroid is shown to result in SAF values that are lower than values of SAF(thyroid<--ET1) by factors of approximately 2-3, and lower than values of SAF(thyroid<--ET2) by factors of approximately 30 at photon energies >50 keV. At energies <50 keV, values of SAF(thyroid<--ET2) are shown to be orders of magnitude higher than the ICRP 66 default given by SAF(thyroid<--brain).

An endothelin urinary hyperexcretion, which is not counterbalanced by an adequate increase in cGMP biosynthesis, was previously detected in some patients with IgA Nephropathy (IgAN). Since this imbalance might potentiate local ET1-mediated hemodynamics effects, 9 IgAN patients with an increased >> or = 0.1) urinary ET1/cGMP ratio (group 1) and 5 IgAN patients with comparable renal function and reduced ET1/cGMP ratio (group 2) were given standard doses of isosorbide 5 mononitrate (as a nitric oxide source). Blood nitric oxide (NO) levels, as detected by electron paramagnetic resonance, significantly increased after isosorbide administration (p < 0.01) and decreased after drug discontinuation in both groups. Nitric oxide levels were significantly related with those of the effective renal plasma flow (p < 0.02), but not with the glomerular filtration rate. Proteinuria levels significantly decreased after drug administration (p < 0.009) in group 1 and returned to baseline levels thereafter, except two cases showing persisting low levels. Values of filtration fraction in the same group decreased after iso5M administration (p < 0.02 compared to basal levels). These results may possibly be related to the counterbalancing effects of nitric oxide on endothelin-mediated mesangial contraction.

Background: Platelets are the key factor in primary hemostasis. It has been shown that chronic altitude exposure increases platelets' aggregability. Nevertheless, data about acute effects and the underlying mechanisms are sparse. Methods: Sixteen healthy volunteers were examined in our hospital (519 m alt.) and 30 minutes after arrival in the environmental research station on the Zugspitze Mountain (2656 m alt.). Serum levels of soluble p-selectin were examined to elucidate platelet activation. In addition, serum levels of chromogranin A (CGA) as a measure of adrenergic activation, endothelin 1 (ET-1) representing pulmonary vascular tone and monocyte chemoattractant protein-1 (MCP-1) as a measure of inflammatory response were examined. Results: Acute altitude exposure induced a significant increase of p-selectin (116 ± 4.8 pg/mL vs. 132 ± 6.2 pg/mL; p < 0.01). Whereas MCP-1 was significantly lowered (538 ± 50.6 pg/mL to 470 ± 41.1 pg/mL; p = 0.02) and CGA was not altered significantly (88 ± 47.4 ng/mL vs. 79 ± 44 ng/mL; p = 0.22), ET1 was increased significantly from 0.8 ± 0.07 pg/mL to 1.15 ± 0.09 pg/mL (p < 0.01). Conclusion: Our study could demonstrate relevant platelet activation that was accompanied by a 44% increase of ET-1. This activation might obtain clinical relevance in patients with pre-existing cardiovascular disease as a trigger for acute events.

Endothelin-1 (ET1), a 21-amino acid polypeptide, produced mainly in endothelial cells is the most potent mammalian vasoconstrictor peptide known. Haemorrhagic hypotension is accompanied by the increase in plasma ET1 concentration. The significance of this effect, however, is not clear. This paper reviews the causes of the rise in ET1 plasma concentration and the role of ET1 in cardiovascular regulation in haemorrhagic shock.

This study aimed to confirm the effects of Tibet kefir milk (TKM) on gut microbiota and metabolism. An obesity model was established by feeding a high-fat diet (HFD) to human-microbiota-associated rats. Next-generation sequencing and ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry were applied for gut microbiota and untargeted metabolomics, respectively. After 8 weeks of feeding, the enterotype in the HFD group was switched from ET1 (Prevotella/Akkermansia-dominant) to ET2 (Bacteroides/Akkermansia-dominant). Branched-chain amino-acids- and aromatic amino-acids-metabolism increased, and taurine-conjugated bile acids decreased in the HFD group. Compared with the HFD group, taurocholic acid increased in the TKM1 group, while l-threonine decreased, and equol, taurochenodeoxycholate, and taurodeoxycholic acid increased in the TKM2 group. The metabolite alteration suggested restorative bile acid metabolism, modified metabolic pattern of amino acids, and elevation of anti-obesity factors in the TKM-intervened animals. It can be deduced that changes by TKM intervention in the host gut metabolites are the major contributors to reducing fat deposition.

Keywords: Tibet kefir milk; amino acids; bile acids; enterotypes; equol; untargeted metabolomics.

Two cell lines, RR5.ET-1 and RR1.ET-1, that produce monoclonal antibodies specific for the carboxyl-terminal heptapeptide of endothelin-1 (ET-1) have been cloned and stabilized. An RIA was developed to facilitate the evaluation and characterization of these monoclonal antibodies. The affinity constant of each MAb for ET-1, as determined by Scatchard analysis, was 5.74 x 10(8) M-1 for RR5.ET-1 and 4.15 x 10(7) M-1 for RR1.ET-1. The antibodies reacted specifically with the carboxyl-terminus (ET1ET1-16). As expected, the antibodies cross-reacted with endothelin-2 (ET-2) and endothelin-3 (ET-3), and to a lesser extent, with the closely related sarafotoxins. Both MAbs retained about 55% reactivity with the ET-1 terminal sequence of Asp-Ile-Ile-Trp (ET1ET1ET1-39). These data strongly suggest that the terminal four amino acids of ET-1 are included in the MAb binding site. More importantly, the terminal Trp21 must be free, not linked to Val22 to retain reactivity with either of the MAbs.

Hemodynamic parameters were measured by ballon tipped catheter in 11 patients with COPD and plasma levels of endothelin1 (ET1), cAMP and cGMP were detected by radioimmunoassay. The results indicated that 3,4-dihydroxyacetophenone (DHAP) gives with an i.v. dose of 640mg could reduce (1) 15% of mean pulmonary arterial pressure, 39% of pulmonary vascular resistance and 21% of systemic vascular resistance; (2) but not effect on systemic arterial pressure and blood gas analysis; (3) decrease the plasma ET1 as well as cGMP level (P < 0.01, P < 0.05 respectively). The authors think that the decrease of pulmonary arterial pressure in COPD patients may be related to the lowering of plasma ET1 level and the change of the cAMP to cGMP ratio.

Beta-cypermethrin (β-CY) and its major metabolite 3-phenoxybenzoic acid (3-PBA) spread extensively in the environment because of utilization in agricultural and home formulations, exerting negative impact on environment as well as human health. Several golden flower fungi were isolated from fu brick tea, by which the biodegradation of β-CY and 3-PBA was evaluated, turning out strain Eurotium cristatum ET1 had the highest capacity. Furthermore, β-CY and 3-PBA degradation rates were positively correlated with biomass of E. cristatum ET1, and the processes of degradation fitted well with a first-order kinetic equation. The half-lives of β-CY and 3-PBA ranged from 3.382 to 11.517 days and 1.749 to 3.194 days, respectively, under different substrate concentrations, incubation temperatures, and pH values. The degraded products were analyzed using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry, and results showed that E. cristatum ET1 degrades β-CY by transforming it into 3-PBA, which is then gradually metabolized into phenol and catechol. Moreover, E. cristatum ET1 showed efficiency in degrading these metabolites. Our results suggest that this strain is a potential microorganism for bioremediation of pesticide-contaminated environments and fermented foods.

Calcium channel blockers are now recommended for the treatment of stable angina but few studies have been carried out comparing the efficacy of verapamil and diltiazem in this indication. The short-term efficacy of these two drugs was compared in a double-blind crossover trial in 12 patients. The following protocol was used, 24 hour selection period followed by two crossover treatment periods versus double placebo. Exercise stress tests were performed 2 hours after the last dose at the end of each treatment period. Each patient underwent 3 stress tests: the first during the selection period whilst taking verapamil and diltiazem placebo (ET0), the second after the first treatment period at day 7 (ET1) and the third after the second treatment period at day 14 (ET2). A comparison of exercise capacity (ET0 to ET1 and ET2) showed improved effort tolerance and an increase in the ischaemic threshold with calcium blocker therapy. The duration of effort, the maximum sustained load, the rate-pressure product and the time to ST depression were all significantly increased. On the other hand, there were no significant changes in the percentage theoretical maximum heart rate attained, the heart rate at which ST depression occurred, the maximum ST depression and the incidence of angina. A comparison between ET1 and ET2 did not show any difference in the parameters of maximum effort or of the appearance of myocardial ischaemia. The comparison of exercise stress tests performed after treatment with verapamil and after diltiazem showed that the total duration of exercise, the maximum sustained load (in watts) and the rate-pressure product were identical.(ABSTRACT TRUNCATED AT 250 WORDS)

Seventy-three Australian isolates of Salmonella Enteritidis (SE) were analysed by multilocus enzyme electrophoresis (MEE) using a polyacrylamide gel system. Analysis of 11 enzyme loci identified eight electrophoretic types (ETs), with 61 of the isolates assigned to ET1, and 72 isolates considered to represent a clonal lineage. Representative isolates of each of the Australian ETs were then compared with isolates from England, Germany and the United States, using a starch gel system and 13 enzyme loci. The overseas isolates formed a single ET with representatives of the major Australian ET. It is concluded that Australian isolates of SE are closely related genetically to those from countries in which egg-borne transmission is common.

Endothelins are powerful vasoconstrictor peptides that play numerous other roles. Endothelin-1 (ET1) is the principal isoform produced by the endothelium in the human cardiovascular system. Endothelin-3 (ET3) and its rPptor affinity have been demonstrated to support neuronal repair mechanisms throughout life. In multiple sclerosis (MS), the role of vasoactive peptides are not well defined. Here we focus on ET3, specifically the plasma levels between MS patients and healthy subjects. Furthermore, we evaluated the changes in ET1 and ET3 plasma levels during different disease phases, the correlation between ET3 and cerebral circulation time, and the relationship between ET1 and ET3. In MS patients, the ET3 plasma levels were altered in a time-dependent manner. These results could support a putative role of ET3 in neuroprotection and/or neuroimmune modulation over time.

Keywords: blood-brain barrier; cerebral circulation time; endothelin-3; multiple sclerosis (MS); neuroimmune modulation.

Time course and extent of strophanthin-K induced disturbances of flash electroretinogram (F-ERG) has been observed in 12 albino rabbits treated by a single dose of 1, 3 and 9 ug/0.1 ml of intravitreal injection. A phenomenon of the dependence of a- and b-wave amplitude changes on dosage was demonstrated. A 9 ug/0.1 ml dose caused a flat a- and b-wave showing the F-ERG wave could be completely suppressed by larger dose of strophanthin-K. Two parameters of "attenuation kinetics" are proposed to identify the pharmacodynamics and toxic kinetics on retina as time profile is concerned: 1) B (the slope of attenuation curve); 2) Et1/2 (half attenuative time). B and Et1/2 are helpful in making a tentative identification of the target cells on retina and in demonstrating a synergism or antagonism between drugs if any. The a-wave of F-ERG, having a steeper slope, is more sensitive than b-wave in terms of strophanthin-K toxicity bringing forth a quantitative criterion in visual pharmacology. The attenuation of amplitude in a-wave may therefore be considered as an early response to this drug. The direct pupillary response test were also done pre- and post-strophanthin-K, and the results of this test support that of F-ERG.

Cardiac function was evaluated in rest and after exercise on a cycloergometer in 20 patients with essential hypertension (EH) aged 14 to 19 years and 12 age-matched healthy volunteers. Selected parameters of ECHO examination and mitral flow were assessed, including SV, CO, CI, %SF, EF, LIVDd, IVSd, LVPWd, LVMI, total peripheral vascular resistance, ESS, velocity of wave E. A and E/A index. In all cases, serum ET1 and NPY levels were measured in rest and after exercise, before and after 6-month enalapril therapy. The ETI serum level in hypertensive patients did not differ from controls, while the NPY level was significantly higher in hypertensives. Exercise did not affect the ETI serum concentration, however, it did increase the NPY level. Enalapril therapy had no effect on serum peptide concentrations. Correlation of the ETI serum level with ECHO parameters, including CO, Cl, SV, LIVDd, LVPWd, %SF, TPRI and wave E velocity, as well as correlation of NPY concentration with LIVDd, LVPWd, LVMI, ESS and wave E and A velocity may suggest that these peptides influence left ventricle function and structure disturbances in children with EH.